

Folate Receptor Alpha (FOLR1), Semi-Quantitative Immunohistochemistry, Manual

#### Overview

#### **Useful For**

Diagnosis of epithelial ovarian cancer that may be eligible for treatment with an anti-folate receptor 1 protein antibody

#### **Method Name**

Immunohistochemistry (IHC)

#### **NY State Available**

Yes

## Specimen

## **Specimen Type**

Special

## **Ordering Guidance**

This test may be utilized for all types of ovarian cancers.

## **Shipping Instructions**

Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.

#### **Necessary Information**

A pathology/diagnostic report and a brief history are required.

### Specimen Required

**Specimen Type:** Tissue **Source**: Ovarian tumor

**Supplies:** Pathology Packaging Kit (T554)

Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides

with 4-microns formalin-fixed, paraffin-embedded tissue

**Additional Information:** One slide will be stained with hematoxylin and eosin and returned.

# **Forms**

If not ordering electronically, complete, print, and send an <u>Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains</u>
Request (T763) with the specimen.

# **Reject Due To**



Folate Receptor Alpha (FOLR1), Semi-Quantitative Immunohistochemistry, Manual

Wet/frozen	Reject
tissue	Reject
Decalcified	
paraffin	
embedded	
tissue	
Cytology	
smears	
Non-formalin	
fixed tissue	
including	
alcohol-formali	
n-acetic acid	
(AFA), 95%	
ethanol,	
PREFER	
fixatives or	
Zinc formalin	
Nonparaffin	
embedded	
tissue	
Noncharged	
slides	
ProbeOn slides	

# **Specimen Stability Information**

Specimen Type	Temperature	Time	Special Container
Special	Ambient (preferred)		
	Refrigerated		

# Clinical & Interpretive

#### **Clinical Information**

Folate receptor 1 protein (FOLR1), also known as folate receptor alpha (FRa), is expressed in approximately 90% of ovarian carcinomas and serves as a predictive biomarker for FOLR1-targeted therapy for epithelial ovarian cancer. FOLR1 is a member of the folate receptor family that is reported to be highly expressed in various tumors of epithelial origin but has restricted expression in normal epithelial cells. Positivity for FOLR1 is expressed on greater or equal to 75% of viable tumor cells with moderate and/or strong membrane staining, while less than 75% of viable tumor cells with moderate and/or strong membrane staining is considered negative for FOLR1.



Folate Receptor Alpha (FOLR1), Semi-Quantitative Immunohistochemistry, Manual

#### **Reference Values**

An interpretive report will be provided.

#### Interpretation

Folate receptor 1 protein (FOLR1) is a biomarker that, when positive (at least moderate membranous staining) in greater than or equal to 75% of tumor cells, predicts response to treatment with Elahere (mirvetuximab soravtansine) and has been approved for epithelial ovarian, fallopian tube, or primary peritoneal cancer.(1)

This result should be interpreted in the appropriate clinical context.

#### **Cautions**

This test has been validated for nondecalcified paraffin-embedded tissue specimens fixed in 10% neutral-buffered formalin. Recommended fixation time is between 6 hours and 48 hours. This assay has not been validated on tissues subjected to the decalcification process or use of alternative fixatives for bone and bone marrow specimens or cell blocks.

Age of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.

#### Clinical Reference

- 1. VENTANA FOLR1 (FOR-2.1) RxDx Assay. US Package Insert. Roche Diagnostics; 2022
- 2. Scaranti M, Cojocaru E, Banerjee S, et al. Exploiting the folate receptor alpha in oncology. Nat Rev Clin Oncol. 2020;17(6):349-359
- 3. Necela B, Crozier J, Andorfer C, et al. Folate receptor-alpha (FOLR1) expression and function in triple negative tumors. PLoS One. 2015;10(3):e0122209
- 4. Kobel M, Madore J, Ramus S, et al. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. 2014;111:2297-2307

# **Performance**

## **Method Description**

Immunohistochemistry on sections of paraffin-embedded tissue.(Unpublished Mayo method)

## **PDF Report**

No

## Day(s) Performed

Monday through Friday

## Report Available

5 to 7 days



Folate Receptor Alpha (FOLR1), Semi-Quantitative Immunohistochemistry, Manual

## **Specimen Retention Time**

Until reported

# **Performing Laboratory Location**

Mayo Clinic Laboratories - Rochester Main Campus

## **Fees & Codes**

#### **Fees**

- Authorized users can sign in to <u>Test Prices</u> for detailed fee information.
- Clients without access to Test Prices can contact <u>Customer Service</u> 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact <u>Customer Service</u>.

#### **Test Classification**

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

# **CPT Code Information**

88360

#### **LOINC®** Information

Test ID	Test Order Name	Order LOINC® Value
AFOLR	FOLR1, SemiQuant IHC, Manual	105010-3

Result ID	Test Result Name	Result LOINC® Value
620732	Interpretation	50595-8
621015	Participated in the Interpretation	No LOINC Needed
621016	Report electronically signed by	19139-5
621017	Material Received	81178-6
621018	Disclaimer	62364-5
621019	Case Number	80398-1